Polydex Pharmaceuticals Stock Shares Owned By Insiders
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
Polydex Pharmaceuticals fundamentals help investors to digest information that contributes to Polydex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Polydex Pink Sheet. The fundamental analysis module provides a way to measure Polydex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Polydex Pharmaceuticals pink sheet.
Polydex |
Polydex Pharmaceuticals Company Shares Owned By Insiders Analysis
Polydex Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 0.0% of Polydex Pharmaceuticals are shares owned by insiders. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 100.0% higher than that of the company.
Polydex Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Polydex Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Polydex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Polydex Pharmaceuticals by comparing valuation metrics of similar companies.Polydex Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Polydex Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 | |||
| Profit Margin | (0.25) % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 3.43 M | |||
| Number Of Shares Shorted | 11 | |||
| Price To Earning | 12.33 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 4.05 M | |||
| Gross Profit | 970.3 K | |||
| EBITDA | (568.16 K) | |||
| Cash And Equivalents | 870.3 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 301.49 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 5.88 X | |||
| Book Value Per Share | 1.44 X | |||
| Cash Flow From Operations | (238.54 K) | |||
| Short Ratio | 0.02 X | |||
| Earnings Per Share | (0.13) X | |||
| Number Of Employees | 21 | |||
| Beta | 0.33 | |||
| Market Capitalization | 2.23 M | |||
| Total Asset | 6.56 M | |||
| Retained Earnings | (19.53 M) | |||
| Working Capital | 2.12 M | |||
| Current Asset | 3.41 M | |||
| Current Liabilities | 1.28 M | |||
| Z Score | 1.4 |
About Polydex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Polydex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Polydex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Polydex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |